| Cystic Fibrosis
Symdeko vs Alyftrek
Side-by-side clinical, coverage, and cost comparison for cystic fibrosis.Deep comparison between: Symdeko vs Alyftrek with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAlyftrek has a higher rate of injection site reactions vs Symdeko based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Alyftrek but not Symdeko, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Symdeko
Alyftrek
At A Glance
Oral
Twice daily
CFTR corrector/potentiator
Oral
Once daily
CFTR modulator (corrector/potentiator)
Indications
- Cystic Fibrosis
- Cystic Fibrosis
Dosing
Cystic Fibrosis Adults and patients >=12 years, or patients 6 to <12 years weighing >=30 kg: tezacaftor 100 mg/ivacaftor 150 mg in the morning and ivacaftor 150 mg in the evening, approximately 12 hours apart, with fat-containing food; patients 6 to <12 years weighing <30 kg: tezacaftor 50 mg/ivacaftor 75 mg in the morning and ivacaftor 75 mg in the evening, approximately 12 hours apart, with fat-containing food. Dose adjustment required for moderate or severe hepatic impairment and for co-administration with CYP3A inhibitors.
Cystic Fibrosis (ages 6 to <12, weight <40 kg) Three tablets of vanzacaftor 4 mg/tezacaftor 20 mg/deutivacaftor 50 mg once daily orally with fat-containing food.
Cystic Fibrosis (ages 6 to <12, weight >=40 kg; ages >=12) Two tablets of vanzacaftor 10 mg/tezacaftor 50 mg/deutivacaftor 125 mg once daily orally with fat-containing food.
Contraindications
—
—
Adverse Reactions
Most common (>=3%) headache, nausea, sinus congestion, dizziness
Serious transaminase elevations, hypersensitivity reactions including anaphylaxis, intracranial hypertension, neuropsychiatric events including suicidal thoughts and behaviors, cataracts, distal intestinal obstruction syndrome
Postmarketing anaphylaxis, rash, intracranial hypertension, anxiety, depression, suicidal ideation and behavior, insomnia
Most common (>=5%) Cough, nasopharyngitis, upper respiratory tract infection, headache, oropharyngeal pain, influenza, fatigue, ALT increased, rash, AST increased, sinus congestion
Serious Drug-induced liver injury and liver failure, hypersensitivity reactions including anaphylaxis, intracranial hypertension, neuropsychiatric events including suicidal thoughts and behaviors, cataracts
Postmarketing Intracranial hypertension, anxiety, depression, suicidal ideation and behavior, insomnia
Pharmacology
Tezacaftor/ivacaftor is a CFTR corrector/potentiator combination; tezacaftor facilitates cellular processing and trafficking of mutant CFTR protein (including F508del-CFTR) to the cell surface, while ivacaftor potentiates CFTR channel-open probability, together increasing the quantity and function of CFTR at the cell surface and resulting in increased chloride transport.
Vanzacaftor and tezacaftor are CFTR correctors that bind to different sites on the CFTR protein to facilitate cellular processing and trafficking of mutant CFTR (including F508del) to the cell surface; deutivacaftor is a CFTR potentiator that enhances channel open probability at the cell surface, resulting in increased CFTR quantity and function.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Symdeko
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
Alyftrek
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Symdeko
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (1/8)
Alyftrek
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (0/8)
Humana
Symdeko
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (2/3)
Alyftrek
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Cystic Fibrosis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Cystic Fibrosis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SymdekoView full Symdeko profile
AlyftrekView full Alyftrek profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.